|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.870 HKD | -4.37% |
|
+10.07% | -6.64% |
| 06-18 | CSPC Pharma's Tumor Drug Gets Trial Nod from US FDA | MT |
| 06-18 | CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China | MT |
| Market Cap | 89.98B 11.47B 10.04B 9.25B 8.58B 16.28B 1,089B 16.54B 111B 43.15B 537B 43.07B 42.14B 1,857B | P/E 2026 * |
11x | P/E 2027 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 78.93B 10.06B 8.81B 8.12B 7.52B 14.28B 955B 14.51B 97.32B 37.85B 471B 37.78B 36.97B 1,629B | EV / Sales 2026 * |
2.22x | EV / Sales 2027 * | 2.18x |
| Free-Float |
67.42% | Yield 2026 * |
4.56% | Yield 2027 * | 4.65% |
| 1 day | -4.37% | ||
| 1 week | +10.07% | ||
| Current month | +12.91% | ||
| 1 month | +8.70% | ||
| 3 months | -18.95% | ||
| 6 months | -11.17% | ||
| Current year | -6.64% |
| 1 week | 7.28 |  | 8.58 |
| 1 month | 6.53 | | 8.58 |
| Current year | 6.53 | | 10.96 |
| 1 year | 6.53 | | 11.63 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 11.9 |
| 10 years | 3.47 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Cai
CEO | Chief Executive Officer | 46 | 2025-12-18 |
Qing Jie Wei
COO | Chief Operating Officer | 56 | 2025-12-18 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 44 | 2024-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 2011-08-25 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 2012-01-19 |
Bo Wang
BRD | Director/Board Member | 66 | 2012-12-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-22 | Other | Chief Operating Officer | -1,400,000 | 0.0122% | ||
| 06-22 | Other | Director | -700,000 | 0.0061% | ||
| 06-21 | Other | Chairman | 14,650,000 | 0.1271% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.37% | +10.07% | -3.44% | +18.17% | 12B | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,070B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 624B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| -2.58% | -2.07% | +27.62% | +22.57% | 328B | |
| +1.36% | +0.17% | +29.90% | +49.33% | 284B | |
| +1.98% | +4.08% | -25.78% | -39.02% | 217B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 198B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 161B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 135B | |
| Average | +0.33% | +3.00% | +23.90% | +49.94% | 347.95B | |
| Weighted average by Cap. | +1.48% | +1.67% | +41.69% | +87.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35.56B 4.53B 3.97B 3.66B 3.39B 6.43B 430B 6.54B 43.85B 17.05B 212B 17.02B 16.66B 734B | 35.15B 4.48B 3.92B 3.61B 3.35B 6.36B 425B 6.46B 43.34B 16.85B 210B 16.83B 16.46B 726B |
| Net income | 7.9B 1.01B 882M 813M 753M 1.43B 95.64B 1.45B 9.75B 3.79B 47.2B 3.78B 3.7B 163B | 6.9B 880M 770M 710M 658M 1.25B 83.49B 1.27B 8.51B 3.31B 41.21B 3.3B 3.23B 142B |
| Net Debt | -11.05B -1.41B -1.23B -1.14B -1.05B -2B -134B -2.03B -13.63B -5.3B -66B -5.29B -5.18B -228B | -13.34B -1.7B -1.49B -1.37B -1.27B -2.41B -161B -2.45B -16.44B -6.39B -79.65B -6.38B -6.25B -275B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-07 | HK$7.870 | -4.37% | 89,651,208 |
| 26-07-06 | HK$8.230 | +2.88% | 171,801,547 |
| 26-07-03 | HK$8.000 | +5.96% | 179,055,173 |
| 26-07-02 | HK$7.550 | +8.32% | 172,106,946 |
| 26-06-30 | HK$6.970 | -2.52% | 131,819,809 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1093 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
